Mechanical and chemical testing are needed to bring complex drug-delivery products and other combination products to market.
News & Features
Health IT security firm Imprivata has acquired a segment of Caradigm from GE Healthcare. The deal comes just days after GE announced plans to sell off $20 billion worth of assets over the next one to two years.
Medical device companies willing to align their research activities with government objectives can enjoy increased product development opportunities and financial returns.
Sonic experiences matter in medical products. By aligning the process of product sound design with medical guidelines for alerts and alarms, medical devices gain a new opportunity to connect more deeply with their users.
Best-selling author, cardiologist, and digital health researcher Eric Topol hopes artificial intelligence can help bring empathy back to healthcare.
New surgical robotics systems entering the U.S. market may cause a ripple in Intuitive Surgical's sales cycle, but CEO Gary Guthart says the company's experience will ultimately prevail over the incoming competition.
Digital health is gaining steam, but the successes have been limited to small patient groups and studies. Can digital health products get to the next level and impact wide swaths of the population?
In a new warning letter to Magellan Diagnostics, FDA accused the company of several legal violations, including marketing significantly modified versions of two of its blood lead testing systems without regulatory clearance and failing to submit medical device reports after learning of faulty blood test results.
Device makers focused on diabetes care are making strides toward a more effective ecosystem around digital care.
Mu Young Lee, director of new product solutions at Varian Medical Systems, details the design behind the company’s recently unveiled radiotherapy system and talks about an industry shift in the approach to cancer treatment technologies.
A cloud of skepticism has hovered over Abbott for the better part of the year as analysts questioned how well the company could deliver on its promises in the face of certain manufacturing and acquisition-related challenges. But the skeptics were wrong, and CEO Miles White wasn't afraid to gloat about that a bit during the company's third-quarter earnings call.